Gary S Jacob
CIK 1266802 · CHIEF DEVELOPMENT OFFICER · last filed 2026-08-07
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
OKYO price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
420 LEXINGTON AVE STE 2500
NEW YORK, NY 10170
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| OKYO | CHIEF DEVELOPMENT OFFICER | 112,420 | $1.44 | $161.9K | $59.8K | 4 | 2026-08-07 |
| Hepion Pharmaceuticals, Inc. (HEPA) Delisted | Director | 12 | $0.08 | $1 | $19.9K | 6 | 2024-02-21 |
| Virpax Pharmaceuticals, Inc. (VRPX) Delisted | Director | 14 | $0.00 | $0 | $23.8K | 3 | 2022-01-05 |
| CRDF | Director | 21,922 | $0.80 | $17.6K | $49.7K | 4 | 2021-06-15 |
| Cardiff Oncology, Inc. (TROV) Delisted | Director | 148,954 | — | — | $0 | 5 | 2019-06-24 |
| Hepion Pharmaceuticals, Inc. (CTRV) Delisted | Director | — | — | — | $0 | 2 | 2018-07-03 |
| SYNERGY PHARMACEUTICALS, INC. (SGYP) Delisted | Executive Chairman | 595,460 | — | — | $20.0K | 4 | 2018-06-18 |
| Cardiff Oncology, Inc. (TROVW) Delisted | Director | — | — | — | $0 | 7 | 2017-01-05 |
| SYNERGY PHARMACEUTICALS, INC. (SGYPW) Delisted | Chief Executive Officer | 396,999 | — | — | $0 | 13 | 2016-06-27 |
| CALLISTO PHARMACEUTICALS INC (KAL) Delisted | Chief Executive Officer | 1,474 | $1.12 | $1.7K | $0 | 2 | 2007-10-25 |
Recent Filings · Page 3 of 6
57 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-01-25 | Cardiff Oncology, Inc. (TROV) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-01-09 | SYNERGY PHARMACEUTICALS, INC. (SGYP) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-01-04 | Cardiff Oncology, Inc. (TROV) Delisted | Exer (M) | +16,667 | $0 | EDGAR |
| 2017-10-05 | Cardiff Oncology, Inc. (TROV) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-09-06 | Cardiff Oncology, Inc. (TROV) Delisted | Exer (M) | +9,287 | $0 | EDGAR |
| 2017-06-30 | SYNERGY PHARMACEUTICALS, INC. (SGYP) Delisted | Mixed | — | $0 | EDGAR |
| 2017-05-30 | SYNERGY PHARMACEUTICALS, INC. (SGYP) Delisted | Buy (P) | +5,680 | $20.0K | EDGAR |
| 2017-01-05 | Cardiff Oncology, Inc. (TROVW) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-01-04 | Cardiff Oncology, Inc. (TROVW) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-07-20 | Hepion Pharmaceuticals, Inc. (CTRV) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.